基本信息
浏览量:0
职业迁徙
个人简介
Giulio Cossu (GC) is recognized for his pioneering work on skeletal myogenesis and for the first cell therapy trial with stem cells for muscular dystrophy.
He originally showed that neural tube (Vivarelli and Cossu, Dev. Biol. 1986) and, subsequently, dorsal ectoderm (Cossu et al., Development 1996) activate, through different Wnts, distinct myogenic programs in epaxial and hypaxial somitic progenitors, a notion now in developmental biology textbooks. He also pioneered studies on myogenic cell heterogeneity (Cossu and Molinaro, Curr. Topics Dev. Biol. 1987) by showing intrinsic differences among embryonic, foetal and adult myogenic progenitors (Biressi et al. Dev. Biol. 2007) whose molecular basis he recently elucidated (Messina et al. Cell 2010): these studies outlined an unforeseen parallelism with the hematopoietic system, supporting the idea that at least some tissues of developing mammals are built in subsequent stages by different families of progenitors.
In collaboration with M. Buckingham laboratory, Giulio elucidated the hierarchy of the different myogenic regulatory factors (Tajbakhsh et al. Cell 2007) and also identified unexpected expression of one of these factors, Myf5 in non-somitic progenitors such as the neuroectoderm (Tajbakhsh et al. Neuron 1994) and the lateral mesoderm (Salvatori et al. J. Cell Sci. 2005). These observations led to the identification of a bone-marrow derived, circulating myogenic progenitor cell in adult mice (Ferrari et al. Science 1998) whose embryonic precursors were later identified in the dorsal aorta (De Angelis et al. J Cell Biol. 1999). These cells, named mesoangioblasts, are able to proliferate in vitro and contribute to mesoderm tissues upon transplantation (Minasi et al. 2002). Mesoangioblasts were used for the first successful cell therapy protocols of muscular dystrophy in mice and dogs (Sampaolesi et al. Science 2003; Nature, 2006). After characterization of human mesoangioblasts as a subset of muscle pericytes (Dellavalle et al. Nature Cell Biol. 2007) whose lineage was traced in mice (Dellavalle et al. Nature Comm. 2011), these cells were used by GC for a “first in man” phase I/II clinical trial based upon allo-transplantation of donor mesoangioblasts from an HLA-identical donor in patients affected by Duchenne muscular dystrophy. The trial started in March 2011 and is currently in progress with encouraging results in Giulio's previous Institution. Ongoing research focuses on the development of Human Artificial Chromosomes encoding the dystrophin locus which was tested successfully in dystrophic mice (Tedesco et al. Sci. Transl. Med. 2011) and is currently being further developed by inserting additional cDNA that would enhance the efficacy of human DMD mesoangioblasts for autologous cell therapy (i.e. an excisable immortalizing cassette, multiple copies of dystrophin cDNA and an inducible myogenic factor). In parallel iPS cell derived mesoangioblasts (Tedesco et al. Sci. Transl. Med. 2012) have been derived and tested for models of muscular dystrophy where the endogenous number of progenitors may be exhausted or insufficient. Overall , Giulio's research activity is characterized by the unique ability to combine work in developmental biology with cell therapy, successfully translating results obtained in mammalian embryos into clinical protocols in patients.
Giulio is author of almost 200 peer-reviewed publications; he has been invited as speaker in most meetings on myogenesis and stem cells and has organized EMBO workshops and Gordon Conferences on this topic. He receives funding from many national and international agencies, such as Telethon, Duchenne Parent Project, Human Frontiers Science Organization, European Community, European Research Council and others.
He originally showed that neural tube (Vivarelli and Cossu, Dev. Biol. 1986) and, subsequently, dorsal ectoderm (Cossu et al., Development 1996) activate, through different Wnts, distinct myogenic programs in epaxial and hypaxial somitic progenitors, a notion now in developmental biology textbooks. He also pioneered studies on myogenic cell heterogeneity (Cossu and Molinaro, Curr. Topics Dev. Biol. 1987) by showing intrinsic differences among embryonic, foetal and adult myogenic progenitors (Biressi et al. Dev. Biol. 2007) whose molecular basis he recently elucidated (Messina et al. Cell 2010): these studies outlined an unforeseen parallelism with the hematopoietic system, supporting the idea that at least some tissues of developing mammals are built in subsequent stages by different families of progenitors.
In collaboration with M. Buckingham laboratory, Giulio elucidated the hierarchy of the different myogenic regulatory factors (Tajbakhsh et al. Cell 2007) and also identified unexpected expression of one of these factors, Myf5 in non-somitic progenitors such as the neuroectoderm (Tajbakhsh et al. Neuron 1994) and the lateral mesoderm (Salvatori et al. J. Cell Sci. 2005). These observations led to the identification of a bone-marrow derived, circulating myogenic progenitor cell in adult mice (Ferrari et al. Science 1998) whose embryonic precursors were later identified in the dorsal aorta (De Angelis et al. J Cell Biol. 1999). These cells, named mesoangioblasts, are able to proliferate in vitro and contribute to mesoderm tissues upon transplantation (Minasi et al. 2002). Mesoangioblasts were used for the first successful cell therapy protocols of muscular dystrophy in mice and dogs (Sampaolesi et al. Science 2003; Nature, 2006). After characterization of human mesoangioblasts as a subset of muscle pericytes (Dellavalle et al. Nature Cell Biol. 2007) whose lineage was traced in mice (Dellavalle et al. Nature Comm. 2011), these cells were used by GC for a “first in man” phase I/II clinical trial based upon allo-transplantation of donor mesoangioblasts from an HLA-identical donor in patients affected by Duchenne muscular dystrophy. The trial started in March 2011 and is currently in progress with encouraging results in Giulio's previous Institution. Ongoing research focuses on the development of Human Artificial Chromosomes encoding the dystrophin locus which was tested successfully in dystrophic mice (Tedesco et al. Sci. Transl. Med. 2011) and is currently being further developed by inserting additional cDNA that would enhance the efficacy of human DMD mesoangioblasts for autologous cell therapy (i.e. an excisable immortalizing cassette, multiple copies of dystrophin cDNA and an inducible myogenic factor). In parallel iPS cell derived mesoangioblasts (Tedesco et al. Sci. Transl. Med. 2012) have been derived and tested for models of muscular dystrophy where the endogenous number of progenitors may be exhausted or insufficient. Overall , Giulio's research activity is characterized by the unique ability to combine work in developmental biology with cell therapy, successfully translating results obtained in mammalian embryos into clinical protocols in patients.
Giulio is author of almost 200 peer-reviewed publications; he has been invited as speaker in most meetings on myogenesis and stem cells and has organized EMBO workshops and Gordon Conferences on this topic. He receives funding from many national and international agencies, such as Telethon, Duchenne Parent Project, Human Frontiers Science Organization, European Community, European Research Council and others.
研究兴趣
论文共 1 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn